Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 2
Submit an article Journal homepage
2,237
Views
28
CrossRef citations to date
0
Altmetric
Original Research

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

Shamaila Munir AhmadCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Evelina MartinenaiteCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Morten HolmströmCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Hematology, Zealand University Hospital, DK-4000Roskilde, DenmarkORCID Iconhttps://orcid.org/0000-0002-3764-8578
ORCID Icon,
Mia Aaboe JørgensenCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Özcan MetCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Claudia NastasiDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Uffe KlausenCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, DenmarkORCID Iconhttps://orcid.org/0000-0001-8932-0374
ORCID Icon,
Marco DoniaCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Lars Møller PedersenDepartment of hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
,
Lars MunksgaardDepartment of Hematology, Zealand University Hospital, DK-4000Roskilde, Denmark
,
Niels ØdumDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Anders WoetmannDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
,
Inge Marie SvaneCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark
&
Mads Hald AndersenCenter for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730Herlev, Denmark;Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
 show all
Article: e1390641 | Received 17 Aug 2017, Accepted 05 Oct 2017, Published online: 01 Nov 2017

References

  • Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia. 2014;28:1784–1792. doi:10.1038/leu.2014.108. PMID:24691076
  • Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J et al. PD-L2 expression in human tumors: Relevance to Anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23:3158–3167. doi:10.1158/1078-0432.CCR-16-1761. PMID:28619999
  • Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A. 2016;113:E7769–E7777. doi:10.1073/pnas.1607836113. PMID:27837027
  • Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331. PMID:18173375
  • Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin Lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–2697. doi:10.1200/JCO.2016.66.4482. PMID:27069084
  • Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L et al. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology. 2015;4:e1026530. doi:10.1080/2162402X.2015.1026530. PMID:26405585
  • Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–1288. doi:10.1038/leu.2013.355. PMID:24270737
  • Solito S, Pinton L, Mandruzzato S. In Brief: Myeloid-derived suppressor cells in cancer. J Pathol. 2017;242(1):7–9. doi:10.1002/path.4876. PMID:28097660
  • Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK et al. HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Research. 2013;73:1674–1776. doi:10.1158/0008-5472.CAN-12-3507.
  • Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia. 2013;27:2251–2253. doi:10.1038/leu.2013.118. PMID:23660624
  • Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology. 2013;2:e23991. doi:10.4161/onci.23991. PMID:23734334
  • Ahmad SM, Larsen SK, Svane IM, Andersen MH. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia. 2014;28:236–238. doi:10.1038/leu.2013.261. PMID:24091833
  • Ahmad SM, Svane IM, Andersen MH. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J. 2014;4:230–233. doi:10.1038/bcj.2014.50.
  • Larsen SK, Munir S, Woetmann A, Froesig TM, Odum N, Svane IM et al. Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia. 2013;27:2332–2340. doi:10.1038/leu.2013.196. PMID:23812418
  • Martinenaite E, Ahmad SM, Hansen M, Met O, Westergaard MW, Larsen SK et al. CCL22-specific T cells: Modulating the immunosuppressive tumor microenvironment. Oncoimmunology. 2016;5:e1238541. doi:10.1080/2162402X.2016.1238541. PMID:27999757
  • Met O, Balslev E, Flyger H, Svane IM. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat. 2011;125:395–406. doi:10.1007/s10549-010-0844-9. PMID:20336365
  • Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol. 2012;792:185–196. doi:10.1007/978-1-61779-325-7_15. PMID:21956511
  • Rammensee HG, Falk K, Roetzschke O. MHC molecules as peptide receptors. Curr Biol. 1995;5:35–44. PMID:7697344
  • Andersen MH. Immune regulation by self-recognition: Novel possibilities for anticancer immunotherapy. J Natl Cancer Inst. 2015;107:154. doi:10.1093/jnci/djv154.
  • Andersen MH. Anti-regulatory T cells. Semin Immunopathol. 2016;39(3):317–326. doi:10.1007/s00281-016-0593-x.Review. PMID:27677755
  • Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002;25:97–138. doi:10.1097/00002371-200203000-00001. PMID:12074049
  • Rhee F. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system. Clin Cancer Res. 2007;13:1353–1355. doi:10.1158/1078-0432.CCR-06-2650. PMID:17332275

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.